Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital (NCC/NCRCC/Cancer Hospital), Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
School of Public Health, Affiliated Cancer Hospital, Xinjiang Medical University, Xinjiang, China.
Cancer. 2021 Jun 1;127(11):1880-1893. doi: 10.1002/cncr.33445. Epub 2021 Mar 30.
Colorectal cancer (CRC) is the third most common cancer in China, however, publicly available, descriptive information on the clinical epidemiology of CRC is limited.
Patients diagnosed with primary CRC during 2005 through 2014 were sampled from 13 tertiary hospitals in 9 provinces across China. Data related to sociodemographic characteristics, the use of diagnostic technology, treatment adoption, and expenditure were extracted from individual medical records.
In the full cohort of 8465 patients, the mean ± SD age at diagnosis was 59.3 ± 12.8 years, 57.2% were men, and 58.7% had rectal cancer. On average, 14.4% of patients were diagnosed with stage IV disease, and this proportion increased from 13.5% in 2005 to 20.5% in 2014 (P value for trend < .05). For diagnostic techniques, along with less use of x-rays (average, 81.6%; decreased from 90.0% to 65.7%), there were increases in the use of computed tomography (average, 70.4%; increased from 4.5% to 90.5%) and magnetic resonance imaging (average, 8.8%; increased from 0.1% to 20.4%) over the study period from 2005 to 2014. With regard to treatment, surgery alone was the most common (average, 50.1%), but its use decreased from 51.3% to 39.8% during 2005 through 2014; and the use of other treatments increased simultaneously, such as chemotherapy alone (average, 4.1%; increased from 4.1% to 11.9%). The average medical expenditure per patient was 66,291 Chinese Yuan (2014 value) and increased from 47,259 to 86,709 Chinese Yuan.
The increasing proportion of late-stage diagnoses presents a challenge for CRC control in China. Changes in diagnostic and treatment options and increased expenditures are clearly illustrated in this study. Coupled with the recent introduction of screening initiatives, these data provide an understanding of changes over time and may form a benchmark for future related evaluations of CRC interventions in China.
结直肠癌(CRC)是中国第三大常见癌症,但公开的 CRC 临床流行病学描述性信息有限。
本研究从中国 9 个省的 13 家三级医院中抽取了 2005 年至 2014 年间诊断为原发性 CRC 的患者。从个人病历中提取了与社会人口统计学特征、诊断技术应用、治疗方法采用和支出相关的数据。
在 8465 例患者的全队列中,诊断时的平均年龄为 59.3 ± 12.8 岁,57.2%为男性,58.7%为直肠癌。平均而言,14.4%的患者被诊断为 IV 期疾病,这一比例从 2005 年的 13.5%增加到 2014 年的 20.5%(趋势 P 值<.05)。在诊断技术方面,除了 X 射线的应用减少(平均为 81.6%;从 90.0%降至 65.7%)外,2005 年至 2014 年期间,计算机断层扫描(平均为 70.4%;从 4.5%增至 90.5%)和磁共振成像(平均为 8.8%;从 0.1%增至 20.4%)的应用有所增加。在治疗方面,单独手术是最常见的治疗方法(平均为 50.1%),但在 2005 年至 2014 年期间其应用从 51.3%降至 39.8%;同时,其他治疗方法的应用也同时增加,如单独化疗(平均为 4.1%;从 4.1%增至 11.9%)。每位患者的平均医疗支出为 66291 元(2014 年的价值),从 47259 元增加到 86709 元。
晚期诊断比例的增加对中国 CRC 的控制构成了挑战。本研究清楚地说明了诊断和治疗选择的变化以及支出的增加。再加上最近引入的筛查计划,这些数据提供了对时间变化的了解,并可能为中国未来对 CRC 干预措施的相关评估提供基准。